Showing results (271-280 of 287) with videos related to
Sort By:
Pageof 29
The Journal of Biological Chemistry|December 15, 2019
Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimerMukul Sherekar, Sae-Won Han, Rodolfo Ghirlando, et al.Physical Review Letters|September 29, 2018
Scaling Behavior of Anisotropy Relaxation in Deformed PolymersChristopher N Lam, Wen-Sheng Xu, Wei-Ren Chen, et al.International Journal of Cardiology|May 16, 2021
Stratified medicine using invasive coronary function testing in angina: A cost-effectiveness analysis of the British Heart Foundation CorMicA trialR Heggie, A Briggs, B Stanley, et al.Biochimica Et Biophysica Acta. Biomembranes|May 30, 2024
Neutron spin echo shows pHLIP is capable of retarding membrane thickness fluctuationsHaden L Scott, Violeta Burns-Casamayor, Andrew C Dixson, et al.Journal of Medicinal Chemistry|February 5, 2010
Identification and characterization of 4-chloro-N-(2-{[5-trifluoromethyl)-2-pyridyl]sulfonyl}ethyl)benzamide (GSK3787), a selective and irreversible peroxisome proliferator-activated receptor delta (PPARdelta) antagonistBarry G Shearer, Robert W Wiethe, Adam Ashe, et al.Cell|August 2, 2002
Crystal structure of the glucocorticoid receptor ligand binding domain reveals a novel mode of receptor dimerization and coactivator recognitionRandy K Bledsoe, Valerie G Montana, Thomas B Stanley, et al.Contemporary Clinical Trials|September 24, 2025
Design of a cluster randomized multi-level intervention to decrease barriers to minority cancer patient referral and enrollment to cancer clinical trials: The ACT WONDER<sup>2</sup>S studyDana E Rollison, Melany A Garcia, Rossybelle P Amorrortu, et al.Journal of Medicinal Chemistry|March 30, 2010
Discovery of tertiary sulfonamides as potent liver X receptor antagonistsWilliam J Zuercher, Richard G Buckholz, Nino Campobasso, et al.Nature|February 15, 2002
Structural basis for antagonist-mediated recruitment of nuclear co-repressors by PPARalphaH Eric Xu, Thomas B Stanley, Valerie G Montana, et al.Cancer Medicine|July 7, 2022
Identifying and overcoming barriers to participation of minority populations in clinical trials: Lessons learned from the VanDAAM studyAngelina K C Fink, Amanda C DeRenzis, Shivanshu Awasthi, et al.Pageof 29